Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Current Assets (2023 - 2025)

CG Oncology filings provide 3 years of Current Assets readings, the most recent being $759.5 million for Q4 2025.

  • On a quarterly basis, Current Assets rose 0.7% to $759.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $759.5 million, a 0.7% increase, with the full-year FY2025 number at $759.5 million, up 0.7% from a year prior.
  • Current Assets hit $759.5 million in Q4 2025 for CG Oncology, up from $695.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $759.5 million in Q4 2025 to a low of $194.1 million in Q4 2023.
  • Median Current Assets over the past 3 years was $673.0 million (2025), compared with a mean of $608.0 million.
  • Biggest five-year swings in Current Assets: soared 288.52% in 2024 and later grew 0.7% in 2025.
  • CG Oncology's Current Assets stood at $194.1 million in 2023, then soared by 288.52% to $754.2 million in 2024, then rose by 0.7% to $759.5 million in 2025.
  • The last three reported values for Current Assets were $759.5 million (Q4 2025), $695.8 million (Q3 2025), and $673.0 million (Q2 2025) per Business Quant data.